Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](OSI Pharmaceuticals)"
Count: 73
Selected: 0
| NCT ID | Title |
|---|
| NCT00116909 | A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy | ||
| NCT00116896 | Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors | ||
| NCT00088270 | A Study of OSI-7904L Versus 5-FU/LV as Treatment in Patients With Biliary Tract Cancer | ||
| NCT00073502 | Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer | ||
| NCT01247922 | Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205 | ||
| NCT01032070 | Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma | ||
| NCT01010945 | Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer | ||
| NCT00373425 | A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors | ||
| NCT00294762 | Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC | ||
| NCT00294736 | A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens | ||
| NCT00139620 | A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function | ||
| NCT00085839 | Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2 | ||
| NCT00072631 | Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer | ||
| NCT00040183 | OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer. | ||
| NCT00036647 | OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | ||
| NCT00033241 | Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors | ||
| NCT01567384 | A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies | ||
| NCT01515137 | Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma | ||
| NCT01427205 | Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC) | ||
| NCT01334710 | A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer | ||
| NCT01299220 | Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug) | ||
| NCT01174043 | Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia | ||
| NCT01059305 | Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin | ||
| NCT01038856 | Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera | ||
| NCT01006096 | Erlotinib for Treatment of Psoriasis | ||
| NCT01003938 | Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer | ||
| NCT00871923 | Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer | ||
| NCT00841035 | 7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients | ||
| NCT00739063 | Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer | ||
| NCT00603356 | Phase I Study of OSI-930 and Erlotinib in Cancer Tumors | ||
| NCT00570258 | Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy | ||
| NCT00513851 | Phase 1 Study of OSI-930 in Cancer Patients | ||
| NCT00499655 | Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer | ||
| NCT00497224 | Phase II Trial of Erlotinib in Advanced Pancreatic Cancer | ||
| NCT00385996 | Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer | ||
| NCT00283803 | Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer | ||
| NCT00166426 | Exisulind Versus Placebo After Surgical Removal of the Prostate | ||
| NCT00085826 | A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients | ||
| NCT00073489 | A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL) | ||
| NCT00072618 | Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients | ||
| NCT00046800 | Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer | ||
| NCT00046787 | Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer | ||
| NCT00036036 | Study of CP-461 in Patients With Advanced Renal Cell Cancer | ||
| NCT00380029 | Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer | ||
| NCT00254410 | FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years | ||
| NCT01154335 | Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer | ||
| NCT01557959 | Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | ||
| NCT01257594 | EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas | ||
| NCT01180959 | Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy | ||
| NCT01027598 | Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer |
